
Arvinas Inc (ARVN) Stock Forecast & Price Target
Arvinas Inc (ARVN) Analyst Ratings
Bulls say
Arvinas is positioned as a pioneer in the field of targeted protein degradation and has a strong pipeline of clinical and pre-clinical programs in multiple disease areas. With positive biomarker data and a potential first-in-class drug, ARV-102, for Parkinson's disease, the company has a differentiated opportunity in the market. Additionally, Arvinas' partnerships with large pharmaceutical companies provide potential for commercial success and financial stability. With a robust cash position and a strong portfolio, Arvinas is well-positioned for future growth and success, making it an attractive investment opportunity.
Bears say
Arvinas is facing challenges in hematology and a competitive biotech market, leading to lower expectations in their clinical-stage product candidates. The recent data on their LRRK2 degrader, ARV-102, demonstrated decent results but is not expected to receive approval until 2026, and the stock reflects the challenges rather than the specific data. The company has a strong potential with their BCL6 degrader, ARV-393, and a potential partnership for ex-US commercialization, but the stock currently reflects the delayed timeline for potential approval and the uncertainties in their other therapeutics.
This aggregate rating is based on analysts' research of Arvinas Inc and is not a guaranteed prediction by Public.com or investment advice.
Arvinas Inc (ARVN) Analyst Forecast & Price Prediction
Start investing in Arvinas Inc (ARVN)
Order type
Buy in
Order amount
Est. shares
0 shares